Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
activist, aflibercept, Allan, bevacizumab, BReast, capecitabine, CAPEOX, CAPIRI, colon, colorectal, conventional, CRC, database, distant, Dmitry, DNA, doublet, dual, East, EGFR, exposure, fluoropyrimidine, FOLFIRI, FOLFOX, FOLFOXIRI, gap, gastrointestinal, GLOBOCAN, heading, hypercoagulability, ICI, illiquid, inhibition, internationally, irinotecan, leadership, left, lesser, lung, lymph, main, mainstay, mCRC, MD, microsatellite, Middle, mismatch, MMRp, modest, MSS, NALIRIFOX, NCI, neoantigen, newer, odd, older, oncologist, Opdivo, oversee, oxaliplatin, paired, payroll, phishing, proficient, ramucirumab, resection, role, safeguard, School, scientist, stable, steady, surgical, tailored, threat, trastuzumab, triplet, Tsung, uncommon, University, unusual, upcoming, urgent, UVA, vast, VEGFR, versa, Virginia, virtual, vital, vivo, war, XDNASE, Yervoy, younger
Removed:
accelerating, acting, allogeneic, autoleucel, axicabtagene, beneficially, billion, brexucabtagene, Breyanzi, Bristol, ciloleucel, consisting, counterproductive, dated, deducting, delisted, discourage, distancing, EU, executed, FASB, Gilead, granting, growing, intrinsic, Kite, Kymriah, lisocabtagene, macroeconomic, maraleucel, mechanism, parent, penny, pocket, premature, proof, receivable, repayment, secondary, shortage, social, Squibb, TCR, thousand, tisagenlecleucel, ultimate, Yescarta
Filing tables
Filing exhibits
- 10-K Annual report
- 4.1 Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
- 21.1 Subsidiaries
- 23.1 Consent of Marcum LLP
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 97.1 Policy Regarding the Mandatory Recovery of Compensation
- Download Excel data file
- View Excel data file
XBIO similar filings
Filing view
External links
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in the Registration Statement of Xenetic Biosciences, Inc. on Form S-8 (File Nos. 333-261956, 333-237529, 333-222272 and 333-218024) and on Form S-3 (File Nos. 333-260201, 333-258810, and 333-233769) of our report dated March 21, 2024, with respect to our audits of the consolidated financial statements of Xenetic Biosciences, Inc. as of December 31, 2023 and 2022 and for each of the two years in the period ended December 31, 2023, which report is included in this Annual Report on Form 10-K of Xenetic Biosciences, Inc. for the year ended December 31, 2023.
/s/ Marcum LLP
Marcum LLP
Boston, Massachusetts
March 21, 2024